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Integrative understanding of preclinical and clinical data is imperative to enable informed decisions and reduce the
attrition rate during drug development. The volume and variety of data generated during drug development have
increased tremendously. A new information model and visualization tool was developed to effectively utilize all
available data and current knowledge. The Knowledge Plot integrates preclinical, clinical, efficacy and safety data by
adding two concepts: knowledge from the different disciplines and protein binding.
Internal and public available data were gathered and processed to allow flexible and interactive visualizations. The
exposure was expressed as the unbound concentration of the compound and the treatment effect was normalized
and scaled by including expert opinion on what a biologically meaningful treatment effect would be.
The Knowledge Plot has been applied both retrospectively and prospectively in project teams in a number of
different therapeutic areas, resulting in closer collaboration between multiple disciplines discussing both preclinical
and clinical data. The Plot allows head to head comparisons of compounds and was used to support Candidate
Drug selections and differentiation from comparators and competitors, back translation of clinical data,
understanding the predictability of preclinical models and assays, reviewing drift in primary endpoints over the
years, and evaluate or benchmark compounds in due diligence comparing multiple attributes.
The Knowledge Plot concept allows flexible integration and visualization of relevant data for interpretation in order
to enable scientific and informed decision-making in various stages of drug development. The concept can be used
for communication, decision-making, knowledge management, and as a forward and back translational tool, that
will result in an improved understanding of the competitive edge for a particular project or disease area portfolio.
In addition, it also builds up a knowledge and translational continuum, which in turn will reduce the attrition rate
and costs of clinical development by identifying poor candidates early.
Keywords: Data integration, Preclinical data, Clinical data, Informatics, Visualization, Decision-making, Translational
medicine, Drug development, Knowledge managementBackground
Translational Medicine is the discipline focusing on im-
proving drug discovery and development by bridging the
gap between basic research, clinical development and clin-
ical practice. The key is to identify and quantify bio-
markers that characterize the efficacy and safety profiles at
different stages of drug development. The goal is to build
up the knowledge of a translational continuum from bed
to bench and vice versa, e.g. forward and back translation
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reproduction in any medium, provided the orbetween species is a fundamental process in order to con-
fidently select drug candidates that will demonstrate the
biological and translational hypothesis in clinical develop-
ment, and therefore also reduce the attrition rate [2-4].
Within all development phases, it is imperative to
visualize data to be able to explore and integrate bio-
markers from preclinical and clinical studies for multiple
compounds (for benchmarking, differentiation and to com-
pare forerunners) side-by side for informed decisions. This
requires aggregation of a large amount of data and a holistic
scientific understanding of all biomarkers. The visualization
and integration of different biomarkers and endpointsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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requires input and collaboration between experts from
multiple disciplines in the organization. A platform that ad-
dresses this requires seamless access of data from clinical
trials and preclinical studies. Furthermore, it needs to en-
compass a framework for harmonizing the interpretation
of different types of data, gathered from various species,
patient populations and therapeutic areas. The platform
should, both technically and organizationally, allow use
and reuse of data retrieved from internal and external
sources as well as outputs from pharmacokinetic and
pharmacodynamic modeling and simulations (PKS™). It
should also address both individual and aggregated data
within and across projects. Export of data to other applica-
tions for visualization and integration is key to ensure
flexibility.
A number of commercial informatics tools (e.g. D360
[5], TranSMART [6]) for translational research purposes
allow searching, analyzing and sharing data from multiple
sources, data types and scales, are currently available and
enables export of data to other applications. TranSMART
Knowledge Management Platform is a platform that com-
bines a data repository with intuitive search capabilities
and analysis tools. However, it is based on a gene-centric
approach that supports hypothesis development from a
phenotypic perspective.
Today, pre-defined integration and visualization of data
to answer key questions are performed within the tight
project timelines. The volume and variety of data gener-
ated during drug development have increased tremen-
dously. The Napiergram [7] is widely used within Pharma
to get an overview of preclinical and clinical data, by pre-
senting exposure ranges of unbound drug concentrations
across assay systems and biomarkers. There is a clear need
to facilitate the tedious work of visualizing and managing
data for forward and back translation of compounds, as
well as compound comparison at each milestone.
This paper describes the Knowledge Plot, a new transla-
tional framework for effective and flexible integration of
preclinical and clinical data using a project-centric ap-
proach. The Plot, utilize current knowledge and desired
effect levels for each biomarker and opens up for a trans-
parent discussion and holistic understanding. The princi-
ples of how to construct a Knowledge Plot will be outlined,
as well as retrospective and prospective use cases, demon-
stration of the translational continuum, and how it is im-
perative to use real-time data integration.
Method
A target centric database was built and used as an inter-
mediate data platform to manage the complex data in the
translational space. Here, an Oracle database was used for
data warehousing, Python for web-based data entering-
GUI and TIBCO Spotfire for visual analytics. TheKnowledge Plot approach is not technology dependent but
interoperability within the system landscape should be
taken into account. Ultimately, the technical solution is in-
tegrated with existing databases in-house as well as rele-
vant external databases. Raw or processed data from the
different studies were extracted from various data sources,
reports and scientific articles. Data are typically aggregated
for each dose or treatment group, but individual data can
also be applied. Data sources used in this work are generic-
ally described in Figure 1.
The Knowledge Plot
The basic Knowledge Plot has unbound concentration of
the compound(s) of interest on the horizontal axis and a
normalized and scaled summary measure of the treatment
effect (placebo/vehicle and/or baseline controlled) for an
endpoint on the vertical axis. The scaled treatment effect
is expressed as an index and it is called the Treatment Ef-
fect Index (TEI), where a value of 100 means a Meaningful
Effect and is defined as:
Treatment Effect Index TEIð Þ ¼ 100 Treatment Effect
Meaningful Effect
The Treatment Effect Index is calculated by normaliz-
ing the effect observed in the treatment group (Treat-
ment Effect in the formula above) with the effect value
that is considered to be relevant (biologically meaning-
ful, i.e. Meaningful Effect above). The Treatment Effect
is calculated for the actual endpoint taking account of
the study design and potentially other facts important to
get an unbiased estimate of the Treatment Effect (see ex-
amples of effect formulas that can be used to derive the
Treatment Effect in Table 1). The Meaningful Effect is
set according to thresholds pre-defined by key opinion
leaders and/or internal expertise. Examples of Meaning-
ful Effect criteria for clinical endings and biomarkers
are: Target Product Profile and Target Product Claims
criteria’s, clinical lab values above upper-limit of normal
and per-cent of subjects reporting a certain type of se-
verity of an adverse event. Examples for preclinical end-
points and biomarkers; pre-defined criteria’s in the
Candidate Drug Target Profile or an effect level defined
by a clinically validated reference drug.
The TEI should be transparent with a clear rationale,
which is agreed within the project team or skill network or
dictated by a governance body. TEI and the corresponding
rationale are documented in the database in order to sup-
port a common understanding between experts of different
endpoints. There are similarities between the previously
published Clinical Utility Index [8-10] and the TEI
presented in this paper. Hence, a comparison is outlined in
the Discussion-section. Regarding the interpretation of
TEI, a TEI value of 0 means no effect of treatment, a value
Figure 1 Schematic overview of the knowledge plot data warehouse including the different sources. Data can be integrated for different
purposes, i.e. validation of platforms, overview of project data, decision-making, due diligence, benchmarking, and predictability of preclinical
models and back translation of clinical data.
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sired direction but the size of the effect has not reach the
Meaningful Effect, a negative TEI value means that the ef-
fect goes in the undesired direction, and a value above 100
means that the effect is greater than the Meaningful Effect.
The left part of Figure 2, illustrates the traditional way
of exploiting and visualizing data using different charts,
e.g. bar, line and scatter. The right part of Figure 2 shows
an example of how similar types of data are visualized in a
Knowledge Plot. A point coordinate in the Knowledge Plot
represents the mean unbound concentration (horizontal
axis) for a certain dose group and its corresponding mean
Treatment Effect Index (vertical axis) for a certain end-
point. Data points for a certain endpoint are connected
with a line within each study. Note that different doseTable 1 Examples of effect formulas
Effect formula Effect definitio
m Unscaled (e.g. o
m - mbl Change from ba
m - mctrl Change from co
100*((m -mbl) / mbl) Change from ba
100*((m - mctrl) / (mctrl) Change from co
100*(Nsbj,grp/Ngrp – Nsbj,ctrl /Nctrl) Diff in % Event
M; mean response of endpoint at the corresponding exposure level.
mbl; mean response of endpoint at the baseline.
mctrl; mean response of endpoint at the corresponding exposure level in the contro
Ngrp; total number of subjects in the group.
Nsbj,grp; number of subjects that experienced the event in the group.
Nctrl; number of subjects in the control group.
Nsbj,ctrl; number of subjects that experienced the event in the control group.schedules, formulations, route of administration or dur-
ation should be separated as different treatment arms in
the visualization for a certain endpoint. The majority of
plots developed so far are based on group aggregates;
however individual data can be plotted as well. The color
of the point illustrates the type of endpoint (blue for effi-
cacy, red for safety, yellow for target engagement, black
for in vitro data etc.), whereas the shapes indicate the type
of species. The bottom of the Knowledge Plot is similar to
the Napiergram, where data are visualized as either point
estimates (e.g. Ki, Kd, EC50, IC50) or exposure ranges e.g.
no observed adverse effect level (NOAEL (green star)) and
lowest observed adverse effect level (LOAEL (red star))
interval in a 3-month tox study, c.f. lower part of the
right-hand plot in Figure 2. The safety margin or then Unit of reference value
ccupancy, %) %
seline (raw) Same unit as endpoint
ntrol (raw) Same unit as endpoint
seline (%) %
ntrol (%) %
(percentage points) % (percentage points)
l group.































































Figure 2 Traditional visualizations compared to the knowledge plot. The left part demonstrate a mixture of scatter, bar and line plots
combined with tables. The right part illustrates the Knowledge Plot concentration-response profiles by using Treatment Effect Index on the
vertical axis and the unbound concentration on the horizontal axis. Safety endpoints are colored by red and efficacy endpoints are blue to
visualize the therapeutic window, which is the difference in exposure between the blue efficacy endpoint and the red safety endpoint on the
horizontal 100-line. In addition, one point estimate representing a Ki value and a concentration range (no observed adverse effect level (NOAEL)
and the lowest observed adverse effect level (LOAEL)) are shown in the lower part of the graph.
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exposure between efficacy and safety endpoints at the
100-line on the vertical axis. Outputs from pharmacoki-
netic and pharmacodynamics modeling and simulations
are also entered to the database.
In Figure 3, the information model describes the infor-
mation objects that are needed to construct a Knowledge
Plot in a basic situation, i.e. visualization of both safety
and efficacy data from different studies with different
doses and study designs. Other types of visualizations,
such as plotting no adverse effect levels, Ki/Kd and EC50/
IC50 values, pharmacokinetic-pharmacodynamic data
could be constructed in a similar way as outlined in the
basic situation described here.
In addition to data traditionally collected in a study
(e.g. numerical measurements of exposure and end-
points), the Knowledge Plot requires the following
additional information:
i) Study meta data.
Study information describing the study design,
compounds, species/population, study code and
other data outlined only in study documentation.
ii) Controlled terminology.
Terminology is generally consistent within a study,
but across studies and across development programs
the terminology is out of sync. Encoding all the
various entities in a controlled fashion is especially
important for species, endpoints and compounds.iii)Categorization of endpoints.
Grouping and clustering of endpoints in a
hierarchical manner allows comparison across
compounds and species at different levels. In our
approach the levels corresponds to the granularity of
the key question.
At the top level: Is it a safety or efficacy endpoint?
Intermediate level: Which domains does the effect
derive from? (Vital signs, biomarkers, adverse
events etc.)
At the lowest level: What are the effects?
(Increased blood pressure, occurrence of specific
liver signals, number of subjects experience at
least one occasion of dizziness etc.).
iv) Specifications of the Treatment Effect Index.
The specifications of how the Treatment Effect
Index is calculated for each endpoint may vary
between species, target and type of disease etc.
These descriptions outline how the placebo/
vehicle or baseline controlled response is
derived (Treatment Effect Definition) and what
a meaningful clinical or biological effect
(Reference value) is on this scale. Table 1
contains a list of commonly used Treatment
Effect Definitions and their associate brief
explanations. The set of options for
transforming endpoint measurements into a
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Figure 3 Information model. This conceptual information model illustrates all the key information entities (boxes) and relationships (lines) that
are needed to fully utilize the Knowledge Plot. The relationships are of two types; one-to-one or one-to-many, where ‘many’ is illustrated with
filled anchor points. The relationship names are to be read from the entity with the anchor point.
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The unbound fraction is specific for the species/
strain and the compound. The factor allows
comparison of the exposure levels across species by
using the unbound concentrations rather than the
total plasma concentration of the compound.
A data mart is built row-wise by combining maximum
exposure and endpoint values by the treatment group
(in an advanced mode the rows are further divided into
time points and visits). Study meta information, un-
bound fraction (protein binding), treatment informa-
tion, and scaling details are then added to each row.
The unbound concentration is calculated by multiplying
the free fraction by the mean total concentration in
each treatment group. In this paper maximum plasma
concentration (Cmax) and steady-state plasma concen-
tration (Css) are used, but other measures reflecting the
exposure (e.g. area under the curve (AUC)) can be used
if that is more relevant for the actual disease area or
compound properties. Output from pharmacokinetic-
pharmacodynamic modeling is used when there is a lag-
time between maximal exposure and effect (hysteresis)
[2]. Pharmacokinetic data from satellite animals are
used, when no other data are available. As an example, a
list of variables that were collected to build a Know-
ledge Plot is given in Additional file 1: Table S1. For vo-
cabularies, MeDRA [11] were used to describe adverse
events, whilst internally developed vocabularies anddata structures were used for the majority of other data
types. The Treatment Effect is calculated for each end-
point and time point using the corresponding Treat-
ment Effect Definition that corresponds to the study
design. The Treatment Effect is then normalized into
the Treatment Effect Index by using the reference value.
Visualization
All available data from a project/target are exported into a
data mart and loaded into the visualization tool. A tool that
allows interactive visualizations is preferable as it gives pos-
sibility to switch between time, total and unbound concen-
tration on the horizontal axis, as well as between raw data,
the un-normalized treatment effect and Treatment Effect
Index on the vertical axis. Thus, it is possible to visualize a
certain endpoint using either raw or transformed data, or
apply the treatment effect index when exploring the time
or concentration relationships. The dose groups informa-
tion, Treatment Effect Index rationale and other study meta
information are stored in the database and easily accessible.
Scatter plots is the recommended graph-type, where data
points can be connected by a line for each endpoint and
study. Furthermore, an interactive tool allows filtering out
subsets of data to highlight selected endpoints, compounds
and studies of interest. In addition, a tool that can color,
shape, and size the points depending on their attributes
are desired, so is also the possibility to draw trellis plots.
Graphical templates can be optimized for each disease area
or target of interest to enable instant visualization of data.
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The Knowledge Plot uses two concepts, knowledge (c.f.
TEI) and plasma protein binding. The concept of adding
knowledge about each endpoint enables comparison of
efficacy and safety data generated in the same species.
By also adding protein binding for each species, compar-
isons between species, populations and subpopulations
are possible and the number of ways to visualize and in-
tegrate data will be innumerable [2]. The Knowledge
Plot can integrate studies performed on non-equivalent
doses and transparently revile different receptor dens-
ities or pathophysiological mechanisms in different spe-
cies, interference of safety pharmacology/toxicology
endpoints with efficacy endpoints. Trellis plots are
powerful when dissecting data in different ways and
comparing compound profiles. Data from different com-
pounds could either be plotted on top of each other in
the same graph or side-by-side. The flexibility enables a
relative comparison of information/knowledge within or
between compounds by utilizing data from all develop-
ment stages. Data are visualized on the same scale and
uses the same unit, enabling eyeball inspection to com-
pare drug profiles.
The Knowledge Plot was applied retrospectively and
prospectively in selected projects within or across multiple
therapeutic disease areas. In the retrospective analysis,
preclinical and clinical key biomarkers and endpoints were
selected i) for candidate drug selection, benchmarking and
differentiation by utilizing all available knowledge on refer-
ence compounds and competitors, ii) to identify which
data were used at each milestone for decision making, iii)
to compare endpoints used in different subpopulations iv)
back translation of clinical data to build translational con-
tinuum and understand the predictability of preclinical
models and assays, v) evaluation of different compounds
with different mechanism of actions aiming for the same
patient population and vi) evaluate different dose sched-
ules. The first example using the Knowledge Plot concept
demonstrates the relative differences between two com-
pounds (Compound A and B) by comparing their inte-
grated profiles, supporting either candidate drug selection
or benchmarking or differentiation with reference com-
pound or competitor (Figures 4 and 5). The data included
are: in vitro assays; target engagement; in vivo efficacy;
safety pharmacology; and tolerability in early clinical stud-
ies. Each line represents the behavior of a specific end-
point with increasing exposure in different dose groups.
The efficacy endpoint in the rat was calculated using two
different methods (blue stars). Both methods gave similar
profiles and reached the 100-line, e.g. the targeted or
Meaningful Effect level. Target engagement in monkey
and human (yellow circles and triangles) are similar and
appears in both Figures 4 and 5. The difference between
the two compounds is clearly demonstrated in the safetypharmacology endpoint (red stars in Figure 4), where com-
pound A moves towards the 100-line, i.e. getting worse.
Compound B moves in the opposite direction demonstrat-
ing getting better or no effect. The point estimates in the
lower part of the curve are in vitro data (Kd, Ki, EC50 or
IC50) and are there to recall the differences between the
compounds. Their full in vitro profiles were visualized in a
separate graph (unpublished data).
Figure 5 describes the relationship between mild ad-
verse events and target engagement in two early clinical
studies with different study designs, single and multiple
dosing. There is one clear difference between the two
compounds, where the adverse event endpoint for com-
pound A moves towards the 100-line and not for com-
pound B. This type of visualization can support dose
selection, but that requires real-time access to data. The
inclusion of target engagement data enables a better un-
derstanding of the adverse event profiles. The graphs
also stimulate initial discussion of back translation of the
adverse event endpoint to preclinical safety pharmacol-
ogy data in the project team (red points in Figures 4 and
5). Additional data are needed to validate the predict-
ability and face validity of the safety pharmacology end-
point. The Treatment Effect Index helps non-experts to get
a holistic understanding of data. The project centric data-
base enabled fast and flexible integration and visualization
of data. Data were easy to reuse and instantaneously change
the visualization for new critical questions or hypothesis.
Traditional way of exploring data could be done by chan-
ging the concentration from free to total on the horizontal-
axis and Treatment Effect Index to original observed mean
values or reported Effect on the vertical-axis. If no protein
binding are available, data can be visualized using total con-
centration only. The corresponding Napiergram for Com-
pound A and B (Figure 4) are shown in Figure 6, where the
Knowledge Plot concept is applied to Compound B. Note
that the colored line changes from blue to green for the ef-
ficacy endpoint in the Napiergram at exposures that corres-
pond to levels above the 100-line in the Knowledge Plot.
The next example illustrates the value of re-using data
from external sources. The golden standard measure-
ment of efficacy for all approved Alzheimer’s Disease
drugs, the ADAS-Cog endpoint, is visualized in Figure 7.
The trellis plot visualizes results reported from different
Donepezil clinical trials performed in different subpopu-
lations [12-16] using Treatment Effect Index, where the
Treatment Effect is given by an absolute change from
placebo and the Meaningful Effect is a score of 2.0 in a 3-
month study (supported by the clinically relevant level in
Donepezil registered trials). Thus in that case, a TEI of
100 corresponds to a two-point improvement over pla-
cebo in the ADAS-Cog endpoint. The graph clearly dem-
onstrates that the ADAS-Cog score shows different
responsiveness in different subpopulations of Alzheimer’s
Figure 4 Relationship in the knowledge plot between drug candidate and internal or external comparators with focus on preclinical
efficacy and safety: comparison of efficacy and safety data for compound A and B. Both compounds have similar efficacy profiles (blue).
The safety profile for compound A is different from compound B, where compound A moves towards the Meaningful Effect i.e. is expected to
demonstrate safety issues. The yellow curves describe target engagement for monkey (circles) and human (triangles) and will support the holistic
understanding of the relationship between efficacy and safety vs level of target engagement (similar for rat (not shown), monkey and human).
The black triangles in the lower part are human Ki-values for the different receptor subtypes derived from an in vitro assay. Note that there are
two efficacy profiles for each compound, which corresponds to two different ways to assess efficacy. The concept of the Knowledge Plot is
demonstrated here and all details of the biomarker, study information etc. are available in the data warehouse c.f. Appendix. Legends for species:
rat (star), monkey (circle), human (triangle).
Figure 5 Relationship in the knowledge plot between drug candidate and internal or external comparators with focus on adverse
event in single and multiple dose studies: comparison of adverse event frequencies (red triangles) between compound A and B,
including data from both single and multiple ascending dose studies. The adverse event profiles are similar regardless of treatment duration
time for the two compounds, respectively. However, there is a difference between compound A and B, where the former demonstrate a less
favorable safety profile. By including target engagement c.f. Figure 4, there is a possibility to illustrate target related safety. Legends for species:
rat (star), monkey (circle), human (triangle).
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Figure 6 Napiergram for compound A and B. The unbound exposure ranges versus different preclinical and clinical endpoints or biomarkers
using the same data as in Figure 4. The Knowledge Plot concept has been applied to Compound B, where the exposure range above the
Meaningful Effect level is shown by change in color (from blue to green).
Brynne et al. Journal of Translational Medicine 2013, 11:250 Page 8 of 11
http://www.translational-medicine.com/content/11/1/250Disease and that during the last years Donepezil had failed
in several studies. These data were used to compare with
one internal compound where Donepezil was used as a
positive control (unpublished data), thus unbound concen-
tration are used in the trellis plot. Using total concentration
on the horizontal axis, will show the same pattern as sub-
populations and compound are the same in all panels.
The value of real-time forward and back translation to
enable informed decision has been recently been demon-
strated [4]. Both retrospective and prospective integra-
tion of data resulted in improved cross-functional work
and increased transparency of the large amount of com-
pound and project information. Exploitation and inter-
pretation of preclinical and clinical data supported
improved awareness of face validity and predictability ofFigure 7 Performance of ADAS-Cog test in different subpopulations o
demonstrates that there are different responsiveness in ADAS-Cog in differ
3 months. Data are coming from clinical trials reported in the literature [12
from placebo in a three-month time-scale. The ADAS-Cog endpoint is theanimal models and in vitro assays. Retrospective docu-
mentation of all available data and information available
at each milestone for decision-making clearly identified
which preclinical and clinical studies the biomarkers and
endpoints had reached a meaningful effect or a thresh-
old. Another finding was hepatotoxicity in phase II, with
no pre-warnings from preclinical data or early clinical
studies, which clearly demonstrated that additional bio-
markers are needed. The Knowledge Plot concept was also
used to evaluate or benchmark compounds in due dili-
gence (unpublished data). The prospective pilot initiative
also highlighted the requirements on data and infrastruc-
ture for aligning a number of existing translational data
platforms across pre-clinical and clinical domain. It also
exposed the need to develop an enterprise solution inf alzheimer’s disease visualized in the knowledge plot. The Plot
ent subpopulations of Alzheimer’s Disease, treated with Donepezil for
-16] where the Meaningful Effect is defined as a change of 2 scores
clinical outcome used in Alzheimer’s Disease trials.
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which were tailored to the individual project needs [4]. In
addition to unbound and total concentration in plasma,
drug exposures in CSF and brain were compared with effi-
cacy biomarkers for a number of compounds and species
in the prospective study (unpublished data).
The Knowledge Plot approach helps project teams to
handle enormous amounts of information in a flexible
way with limited efforts and without getting information
overload. The Knowledge Plot visualizes and integrates
available data and knowledge in a transparent way by en-
abling a holistic (cross domain) interpretation by taking
all attributes into consideration. As of today we have
about 15 different targets, 50 compounds, 10 species, 17
populations/subpopulations, 260 studies and 100 end-
points in our database and we continue to build the
knowledge bank as new and existing compounds pro-
gress in the pipeline.
Discussion
In this paper, the basic version of the Knowledge Plot has
been presented to illustrate the main idea and how it can
be implemented to support business needs. The concept
can be, and has been, expanded in many different ways.
Some characteristics that have been incorporated into the
Knowledge Plot are: confidence in each observation (con-
fidence intervals, standard error, and number of observa-
tions the summary is based on), individual data, and time
dimension. Others have proposed a scoring system for
biomarker assessment [17] and their translatability [18] in
early drug projects to estimate risks in project and portfo-
lio decisions. This scoring system apply weights on data in
order to avoid weak data sets to have equal impact as
strong data sets by using scores between 1 and 5 (e.g. 5 =
more validated data, more clinically relevant data). This
implies that therapeutic areas with high translational risk
will already up front call for the need to identify more reli-
able biomarkers [19]. Such a weighting procedure can be a
complement in the decision-making process.
The use of expert knowledge to define a desired
Meaningful Effect, is the fundamental principle that dis-
tinguish the Knowledge Plot from methods published by
others. One example is the utility function that is a com-
ponent in the Clinical Utility Index (CUI) [8-10]. The
CUI is a weighted sum of the utilities of all the attributes
that are considered to be important for decision making
in the actual situation. Both the CUI and each of the in-
dividual utilities take values in the (0, 1) range whereas
the TEI can take any value though values in the (0,100)
range are most common. In order to add a new sum-
mary index, in parallel to what is presented in this paper,
you only need to convert it to the (0,100) scale. Clinical
Utility Index can be used alternatively, or be included as
complement, to the Treatment Effect Index.There are some important considerations, in particular
how an index such as the Treatment Effect Index is de-
rived. One is that the random variation in the control
group that is used to normalize against will result in even
larger random variation in the normalized summary index,
in particular when the control group is small in relation to
the variation of the endpoint. Another concern is how to
standardize the placebo/vehicle controlled treatment re-
sponse. The Knowledge Plot uses standardization against
the meaningful effect, which initially can be difficult to de-
fine for explorative endpoints. However, for such end-
points the relative difference between compounds can still
be identified as long as the same meaningful effect value is
used. Note that the reference value should be updated
when more knowledge about the explorative endpoint is
gained. Instead of using a reference value of a meaningful
effect to derive an index it has been suggested to use
the variance, or the standard deviation, to standardize the
treatment effect to a normalized summary index, e.g. the
Clinical Utility Index [8-10]. There are pros and cons with
all methods. The method that suits the particular situation
should be selected depending on how to interpret complex
data and information with visualization techniques. The
main reason why using the Treatment Effect Index is that
it includes the expert opinion on the biological/medical
knowledge identifying at which level an endpoint will give
benefit to the patient. The index is based on current avail-
able treatments so that an index value of 100 will mean a
biological meaningful treatment effect that has a realizable
business value. A Napiergram can be derived by collapsing
the vertical axis in the Knowledge Plot (see Figures 5 and
6, compound B).
Data standards and terminologies are very important in
all data integration initiatives. Especially controlled vo-
cabularies are important in order to compare across spe-
cies, endpoints and studies. There are several available
options that can be used (e.g. MeSH [20], Snowmed [21],
MeDRA [11], NCI terminology [22]) as well as data struc-
tures and information models where the CDISC-suite [23]
(SEND and SDTM) or a Triple Store solution may be con-
sidered. In general, the terminology used in clinical devel-
opment is more consistent compared to the terminology
in preclinical research.
Evaluating multiple attributes in a prospective manner
and utilization of current information and knowledge
are necessary procedures in order to optimize the prod-
uctivity in future drug development. Visualization, data
mining and knowledge management are all critical cap-
abilities in this process. Currently, several stand-alone
computational tools are used in a manual environment
and data often exists in disconnected databases. Integra-
tion of data is a complex and difficult endeavor. Thus, a
common computational infrastructure will remove many
of the inherent road blocks [24]. In addition, cultural
Brynne et al. Journal of Translational Medicine 2013, 11:250 Page 10 of 11
http://www.translational-medicine.com/content/11/1/250changes have to take place to ensure effective sharing
and integration of data between various functions, such
as Drug metabolism and pharmacokinetics (DMPK),
Pharmacology, Safety and Clinical, and external sources.
The principles enlisted here is key to achieve shorter de-
velopment timelines and will allow more time spent on
building a Translational and Knowledge continuum that
can support all drug development stages. Incorporation
of scientific knowledge allows the organization to make
informed and transparent investment decisions with re-
spect to individual projects as well as the complete port-
folio. Furthermore, using frameworks like the one
presented in this paper serves like a common language
for the spectra of subject matter experts that constitute
a modern drug development team. Each subject matter
expert is accountable for the interpretation within re-
spective domain (i.e. Meaningful Effect), but that same
person can also easily accept the data-driven interpre-
tations from all the other domains, that includes sub-
ject matter expertise from other functions. Ultimately,
we have seen that the Knowledge Plot catalyzes the
build-up of confidence and trust among the team
members, where the discussion have moved from one
experiment at a time to what the experiment is worth
in the context of all available information and know-
ledge. The organizational effects are difficult to quan-
tify, but informed decision making and knowledge
management are central for large research and devel-
oping organizations. In this context the Knowledge
Plot plays a central role and will be of great value for
everyone that embraces its principles.Conclusions
The Knowledge Plot allows a transparent head-to-head
comparison of data across multiple domains. It harmo-
nizes and simplifies the interpretation and enables sci-
entific and informed decision-making in various stages
of drug development. Furthermore, the Knowledge
Plot visualizes the translational and knowledge con-
tinuum, which in turn will reduce the attrition rate and
reduce costs of clinical development by spotting poor
candidates early. It provides a quick overview of what
has been done with a molecule and uncovers hidden
patterns by comparing the molecule with previous
similar molecules and how efficacy and safety profiles
compares with potential competitors and comparators.
Exhaustive information, holistic understanding and in-
tegration of all current knowledge are prerequisites for
effective decision making. Thus, the Knowledge Plot is
a valuable communication, decision-making and know-
ledge management tool that will result in an improved
understanding of the competitive edge for a particular
project or disease area portfolio.Additional file
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